Even at lower doses, tirzepatide can reduce HbA1c more than the highest doses of semaglutide
Patients with active hepatitis or significant liver failure should generally avoid naltrexone
Some states have covered GLP-1 therapy for obesity, while others have narrowed or ended coverage because of cost
uranJCepanecIMaekTStareviKTlak GajgerIVranjeMet al
What this means for patients: It may help reduce appetite It can support better blood sugar balance It may increase energy expenditure It can promote fat loss over time Compared to single or dual-action medications, this is why many providers are closely watching retatrutide effectiveness vs semaglutide in ongoing research
[1] [4] According to NICE guidance (NG28), GLP-1 receptor agonists like Trulicity may be considered when specific criteria are met, such as BMI above 35 kg/m (or lower in certain ethnic groups), or when weight loss would benefit obesity-related comorbidities